Martin Trautmann @trauti

Healthcare operator | Investor (20+ cos) Where data meets reality in medicine Building, fixing, occasionally ranting Tennis & food in between Views my own trautmann.world Joined April 2009

Tweets

357
Followers

264
Following

1K
Likes

1K

Martin Trautmann @trauti

2 months ago

Recently joined Premier to work more closely at the intersection of life sciences, data, and provider systems. What’s striking is how consistent the pattern is: strong ideas → strong data → slow, uneven adoption That last step is where most things break.

0 0 0 19 0

View Details

Martin Trautmann @trauti

2 months ago

@vijaypande @kpfortney @bioagelabs Agree - measurement unlocks capital and talent. The next bottleneck tends to be turning that into something actionable in real-world settings.

0 0 1 25 0

View Details

Martin Trautmann @trauti

2 months ago

@vijaypande @kpfortney @bioagelabs Measurement is necessary. Actionability is what makes it matter.

1 0 0 22 0

View Details

Martin Trautmann @trauti

2 months ago

@EricTopol @Zlatimeyer Discovery is often accidental. Adoption never is. That’s where most of the work in healthcare actually happens.

0 0 0 162 0

View Details

Martin Trautmann @trauti

2 months ago

@julesyoo @JayRughani @vintweeta @CF_Rom The pricing models are evolving quickly. The harder part is still adoption— where incentives, workflows, and behavior don’t move as fast as the technology.

0 0 0 36 0

View Details

Martin Trautmann @trauti

2 months ago

Psychedelics just moved from “interesting science” to real capital allocation. When ~40% of an ARPA-style portfolio concentrates there, it’s not noise. The question now isn’t whether they can work. It’s whether they can make it through: regulation delivery reimbursement

0 0 0 31 0

View Details

Martin Trautmann @trauti

2 months ago

@daniel_kraft Important shift. The challenge is that training can evolve faster than the systems clinicians actually work in. That gap between how medicine is taught and how it’s practiced is where a lot of friction sits.

0 0 1 74 0

View Details

Martin Trautmann @trauti

2 months ago

@fordsmith Exactly. The gap between something working on paper and actually changing behavior in the system is where most things stall.

0 0 0 12 0

View Details

Martin Trautmann @trauti

2 months ago

You can design reimbursement. Changing behavior in healthcare is much harder. That’s often the difference between something working in theory and actually getting used.

1 0 1 52 0

View Details

Martin Trautmann @trauti

2 months ago

@LifeSciVC @AimeeRaleigh13 Life sciences is a smaller slice of venture, but it still resets around data. When the clinical signal is strong enough, capital tends to follow—just on a different timeline.

0 0 0 514 0

View Details

Martin Trautmann @trauti

2 months ago

@BiotechMoe Feels like this ultimately comes down to data. In biotech, capital follows when clinical signal becomes hard to ignore. That’s still what resets the narrative.

0 0 0 16 0

View Details

Martin Trautmann @trauti

2 months ago

@BioProtocol @Bankless @peptai_ Impressive direction. The harder part is less designing a molecule and more everything that follows—validation, development, and getting it into patients. That’s where most of the time and cost still sit.

0 0 0 278 0

View Details

Martin Trautmann @trauti

2 months ago

@adamfeuerstein Hard to ignore OS signals like that in pancreatic cancer.

0 0 0 26 0

View Details

Martin Trautmann @trauti

2 months ago

@CMichaelGibson @statnews Pancreatic cancer has set a pretty high bar for skepticism—so OS deltas like this stand out.

0 0 0 33 0

View Details

Martin Trautmann @trauti

2 months ago

Pancreatic cancer has trained everyone to be skeptical. So when you see phase 3 data showing overall survival at 13.2 months vs. 6.7 months, that gets attention. The bigger point: real OS data still cuts through the noise in oncology. ir.revmed.com/news-releases/…

0 0 0 38 0

View Details

Martin Trautmann @trauti

2 months ago

@EricTopol @CellCellPress Really interesting. Feels like microbiome is moving from “interesting biology” → “potentially actionable signal,” especially in treatment response. Curious how you see this translating into real-world clinical decision-making vs. remaining a research insight?

0 0 2 82 0

View Details

Martin Trautmann @trauti

2 months ago

The biggest misconception in healthcare innovation: People think the problem is lack of ideas. It’s not. It’s: who pays who changes behavior how it fits into workflow The system is actually very good at ignoring good ideas.